Elevated IFN-γ-mediated immune activation has been described in coronary artery disease, acute coronary syndrome, and enlarged abdominal aortic aneurysms [35, –37]; however, to our knowledge, IFN-γ has not been validated as a marker of cardiovascular outcomes. This evidence concerns the gene IFNG and coronary artery disorder.